Sumary of REVERSE-IT: Bentracimab provides immediate, sustained reversal of ticagrelor effects:
- November 15, 2021 3 min read Source/Disclosures Published by: Source: Bhatt DL, et al.
- Presented at: American Heart Association Scientific Sessions;
- Back to Healio An IV monoclonal antibody accomplished quick and sustained reversal of the antiplatelet effects of ticagrelor, according to the REVERSE-IT trial presented at the American Heart Association Scientific Sessions.
- Bhatt The antiplatelet effects of ticagrelor (Brilinta, AstraZeneca), a P2Y12 inhibitor, cannot be reversed by platelet transfusion, so a reversal agent is an unmet need, Cardiology Today Intervention Section Editor Deepak L.
- Bhatt, MD, MPH, executive director of interventional cardiology programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, told Healio.
- “The way ticagrelor binds has allowed development of a monoclonal antibody called bentracimab (PhaseBio), which binds to ticagrelor or its active metabolite and is removed from the circulation.
- “The benefits on platelet function kick in very quickly, by 5 to 10 minutes, and are sustained.